426 related articles for article (PubMed ID: 30856357)
1. CRISPR-Cas in Streptococcus pyogenes.
Le Rhun A; Escalera-Maurer A; Bratovič M; Charpentier E
RNA Biol; 2019 Apr; 16(4):380-389. PubMed ID: 30856357
[TBL] [Abstract][Full Text] [Related]
2. The endless battle between phages and CRISPR-Cas systems in
Philippe C; Moineau S
Biochem Cell Biol; 2021 Aug; 99(4):397-402. PubMed ID: 33534660
[TBL] [Abstract][Full Text] [Related]
3. Molecular organization of the type II-A CRISPR adaptation module and its interaction with Cas9 via Csn2.
Ka D; Jang DM; Han BW; Bae E
Nucleic Acids Res; 2018 Oct; 46(18):9805-9815. PubMed ID: 30102386
[TBL] [Abstract][Full Text] [Related]
4. On the Origin of CRISPR-Cas Technology: From Prokaryotes to Mammals.
Mojica FJM; Montoliu L
Trends Microbiol; 2016 Oct; 24(10):811-820. PubMed ID: 27401123
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9: From a bacterial immune system to genome-edited human cells in clinical trials.
Kick L; Kirchner M; Schneider S
Bioengineered; 2017 May; 8(3):280-286. PubMed ID: 28287876
[TBL] [Abstract][Full Text] [Related]
6. An anti-CRISPR from a virulent streptococcal phage inhibits Streptococcus pyogenes Cas9.
Hynes AP; Rousseau GM; Lemay ML; Horvath P; Romero DA; Fremaux C; Moineau S
Nat Microbiol; 2017 Oct; 2(10):1374-1380. PubMed ID: 28785032
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of NHEJ repair by type II-A CRISPR-Cas systems in bacteria.
Bernheim A; Calvo-Villamañán A; Basier C; Cui L; Rocha EPC; Touchon M; Bikard D
Nat Commun; 2017 Dec; 8(1):2094. PubMed ID: 29234047
[TBL] [Abstract][Full Text] [Related]
8. What history tells us XXXIX. CRISPR-Cas: From a prokaryotic immune system to a universal genome editing tool.
Morange M
J Biosci; 2015 Dec; 40(5):829-32. PubMed ID: 26648028
[No Abstract] [Full Text] [Related]
9. Increasing the efficiency of CRISPR-Cas9-VQR precise genome editing in rice.
Hu X; Meng X; Liu Q; Li J; Wang K
Plant Biotechnol J; 2018 Jan; 16(1):292-297. PubMed ID: 28605576
[TBL] [Abstract][Full Text] [Related]
10. Applications of the CRISPR-Cas9 system in cancer biology.
Sánchez-Rivera FJ; Jacks T
Nat Rev Cancer; 2015 Jul; 15(7):387-95. PubMed ID: 26040603
[TBL] [Abstract][Full Text] [Related]
11. Multiplex genome engineering using CRISPR/Cas systems.
Cong L; Ran FA; Cox D; Lin S; Barretto R; Habib N; Hsu PD; Wu X; Jiang W; Marraffini LA; Zhang F
Science; 2013 Feb; 339(6121):819-23. PubMed ID: 23287718
[TBL] [Abstract][Full Text] [Related]
12. Prediction and diversity of tracrRNAs from type II CRISPR-Cas systems.
Chyou TY; Brown CM
RNA Biol; 2019 Apr; 16(4):423-434. PubMed ID: 29995560
[TBL] [Abstract][Full Text] [Related]
13. Extending CRISPR-Cas9 Technology from Genome Editing to Transcriptional Engineering in the Genus Clostridium.
Bruder MR; Pyne ME; Moo-Young M; Chung DA; Chou CP
Appl Environ Microbiol; 2016 Oct; 82(20):6109-6119. PubMed ID: 27496775
[TBL] [Abstract][Full Text] [Related]
14. Cas9 immunity creates challenges for CRISPR gene editing therapies.
Crudele JM; Chamberlain JS
Nat Commun; 2018 Aug; 9(1):3497. PubMed ID: 30158648
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications.
Friedland AE; Baral R; Singhal P; Loveluck K; Shen S; Sanchez M; Marco E; Gotta GM; Maeder ML; Kennedy EM; Kornepati AV; Sousa A; Collins MA; Jayaram H; Cullen BR; Bumcrot D
Genome Biol; 2015 Nov; 16():257. PubMed ID: 26596280
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 Platforms for Genome Editing in Plants: Developments and Applications.
Ma X; Zhu Q; Chen Y; Liu YG
Mol Plant; 2016 Jul; 9(7):961-74. PubMed ID: 27108381
[TBL] [Abstract][Full Text] [Related]
17. Spacer Acquisition Rates Determine the Immunological Diversity of the Type II CRISPR-Cas Immune Response.
Heler R; Wright AV; Vucelja M; Doudna JA; Marraffini LA
Cell Host Microbe; 2019 Feb; 25(2):242-249.e3. PubMed ID: 30709780
[TBL] [Abstract][Full Text] [Related]
18. The application of the CRISPR-Cas9 system in
Ho J; Zhao M; Wojcik S; Taiaroa G; Butler M; Poulter R
J Med Microbiol; 2020 Mar; 69(3):478-486. PubMed ID: 31935181
[No Abstract] [Full Text] [Related]
19. Cas9 function and host genome sampling in Type II-A CRISPR-Cas adaptation.
Wei Y; Terns RM; Terns MP
Genes Dev; 2015 Feb; 29(4):356-61. PubMed ID: 25691466
[TBL] [Abstract][Full Text] [Related]
20. Diversity of CRISPR-Cas-Mediated Mechanisms of Adaptive Immunity in Prokaryotes and Their Application in Biotechnology.
Savitskaya EE; Musharova OS; Severinov KV
Biochemistry (Mosc); 2016 Jul; 81(7):653-61. PubMed ID: 27449612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
